



**HAL**  
open science

## Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19

Florian Lemaitre, Klemens Budde, Teun van Gelder, Stein Bergan, Roland Lawson, Ofelia Noceti, Raman Venkataramanan, Laure Elens, Dirk Jan a R Moes, Dennis A Hesselink, et al.

### ► To cite this version:

Florian Lemaitre, Klemens Budde, Teun van Gelder, Stein Bergan, Roland Lawson, et al.. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19. *Therapeutic Drug Monitoring*, 2023, 45 (2), pp.191-199. 10.1097/FTD.0000000000001014 . hal-03776369

**HAL Id: hal-03776369**

**<https://hal.science/hal-03776369>**

Submitted on 21 Sep 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when**  
2 **combined with nirmatrelvir/ritonavir in patients with COVID-19**  
3

4 **Florian Lemaitre, PharmD, PhD, 1, 2;** Klemens Budde, MD 3; Teun Van Gelder, MD, PhD 4; Stein  
5 Bergan, PhD 5; Roland Lawson, PharmD, PhD 6; Ofelia Noceti, PharmD, PhD 7; Raman  
6 Venkataramanan, PhD 8; Laure Elens, PhD 9; Dirk Jan A.R. Moes, PharmD, PhD 4; Dennis A.  
7 Hesselink, MD, PhD 10; Tomasz Pawinski, PharmD, PhD 11; Kamisha L. Johnson-Davis, PhD 12;  
8 Brenda C.M. De Winter, PharmD, PhD 13; Smita Pattanaik, MD, DM 14; Mercè Brunet, PhD 15;  
9 Satohiro Masuda, PhD 16 and Loralie J. Langman, PhD 17.

10

|    |   |
|----|---|
| 1  | Univ Rennes, CHU Rennes, Inserm, EHESP, IRSET – UMR S 1085, Rennes, France  |
| 2  | INSERM, Centre d'Investigation Clinique 1414, F-35000 Rennes, France  |
| 3  | Department of Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany   |
| 4  | Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, The Netherlands.  |
| 5  | Department of Pharmacology, Oslo University Hospital and Department of Pharmacy, University of Oslo, Norway.  |
| 6  | University of Limoges, Inserm U1248, Pharmacology & Transplantation, F-87000, Limoges, France.  |
| 7  | National Center for Liver Transplantation and Liver Diseases, Army Forces Hospital, Montevideo, Uruguay   |
| 8  | Department of Pharmaceutical Sciences, School of Pharmacy and Department of Pathology, Starzl Transplantation Institute, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA            |
| 9  | Integrated Pharmacometrics, pharmacogenetic and pharmacokinetics research group (PMGK) Louvain Drug for Research institute (LDRI), catholic University of Louvain (UCLouvain), Brussels, Belgium      |
| 4  | Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, The Netherlands.  |
| 10 | Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands  |
| 11 | Department of Drug Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland   |
| 12 | University of Utah Health Sciences Center and ARUP Laboratories, Salt Lake City, UT, USA  |
| 13 | Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.   |
| 14 | Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA  |
| 15 | Pharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, CIBERehd, Spain |
| 16 | Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Japan   |
| 17 | Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA  |

11

12 **Corresponding Author address:**

13 Florian Lemaitre, PharmD, PhD, Department of Pharmacology, Rennes University Hospital, 2  
14 rue Henri Le Guilloux, 35033, Rennes, France. Tel: 0033 223234713. Fax: 0033 299284184. Mail:  
15 florian.lemaitre@chu-rennes.fr  
16

16

17 **Funding:** No funding has been received for this work

18 **Conflict of interest:** FL received research grants from Astellas Pharma, Sandoz and Chiesi Pharma [Paid  
19 to his institution] and fees to attend meetings from Chiesi Pharma and Sandoz; KB received Honoraria,  
20 research grants from Abbvie, Akebia, Alexion, Astellas, Bristol-Myers Squibb, Calliditas, CSL-Behring,  
21 Chiesi, Fresenius, Hexal, Hookipa, MSD Sharp & Dohme, Neovii, Novartis, Otsuka, Pfizer, Quark, Sanofi,  
22 Shire, UCB Pharma, Veloxis, Vifor, and Vitaeris Pharma; TvG has received lecture fees and study grants  
23 from Chiesi and Astellas, in addition to consulting fees from Roche Diagnostics, Thermo Fisher,  
24 Vitaeris, CSL Behring, Astellas and Aurinia Pharma [all paid to his institution]; DAH has received lecture  
25 fees and consulting fees from Astellas Pharma, Chiesi Pharma, Medincell, Novartis Pharma, Sangamo  
26 Therapeutics and Vifor Pharma. He has received grant support from Astellas Pharma, Bristol-Myers  
27 Squibb and Chiesi Pharma [paid to his institution]. SM received lecture fees from Astellas Pharma,  
28 Novartis Pharma and Otsuka Pharmaceutical Factory. He received consulting fees from Meiji-Seika  
29 Pharma. All other authors declare no conflict of interest.

30

31 **Ethics:** N/A

32

33 **Word count:**

34 Abstract: 190

35 Manuscript: 4825

36

37

38

39 ;

40 **Abstract:**

41 Nirmatrelvir/ritonavir (Paxlovid®) consists of a peptidomimetic inhibitor of the SARS-CoV-2 main  
42 protease (Nirmatrelvir) and a pharmacokinetic enhancer (Ritonavir). It is approved for the treatment  
43 of mild-to-moderate COVID-19. This combination of nirmatrelvir and ritonavir can mediate significant  
44 and complex drug-drug interactions, primarily due to the ritonavir component. Indeed, ritonavir  
45 inhibits the metabolism of nirmatrelvir through cytochrome P450 3A (CYP3A) leading to higher plasma  
46 concentrations and a longer half-life of nirmatrelvir. Co-administration of nirmatrelvir/ritonavir with  
47 immunosuppressant drugs is particularly challenging given the major involvement of CYP3A in the  
48 metabolism of most of these drugs and their narrow therapeutic range. Immunosuppressant drug  
49 exposure will be drastically increased through the potent ritonavir-mediated inhibition of CYP3A  
50 resulting in increased risk of adverse drug reactions. While a decrease in immunosuppressive drug  
51 dosage can prevent toxicity, an inappropriate dosage regimen may also result in insufficient exposure  
52 and a risk of rejection. Here we provide some general recommendations for therapeutic drug  
53 monitoring of immunosuppressive drugs and dosing recommendations when co-administered with  
54 nirmatrelvir/ritonavir. Particularly, tacrolimus should be discontinued or patients should be given a  
55 microdose on day-1 while cyclosporine dosage should be reduced to 20% of the initial dosage during  
56 the antiviral treatment. m-TOR inhibitors dosages should also be adapted while mycophenolic acid  
57 and corticosteroids are expected to be less impacted.

58

59 **Keywords:** Drug-drug interactions; Transplantation; Calcineurin inhibitors, mTOR inhibitors;  
60 Tacrolimus

61

62

## 63 1. Introduction

64 Paxlovid® is a new solid oral formulation indicated for the treatment of mild-to-moderate COVID-19  
65 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who test positive  
66 for direct SARS-CoV-2 virus, and who are at high risk for progression to severe COVID-19 [1-4].

67 Paxlovid® is supplied as 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg  
68 tablet) with all the three tablets taken together orally with or without food twice daily for 5 days [1].  
69 No dosage adjustment is needed in patients with mild renal impairment (eGFR  $\geq$ 60 to  $<$ 90 L/min). In  
70 patients with moderate renal impairment (eGFR  $\geq$ 30 to  $<$ 60 mL/min), the dosage of Paxlovid® is  
71 modified to 150 mg nirmatrelvir and 100 mg ritonavir twice daily for 5 days. However, in patients  
72 with severe renal impairment or severe hepatic impairment, the use of the nirmatrelvir/ritonavir is  
73 not recommended due to limited availability of safety and efficacy data [1, 2].

74

### 75 1.1 Pharmacodynamics:

76 Nirmatrelvir's chemical name is (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-  
77 ((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-  
78 carboxamide] (Figure 1) and is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro),  
79 also referred to as 3C-like protease (3CLpro) or nsp5 protease. Inhibition of SARS-CoV-2 Mpro  
80 renders it incapable of processing polyprotein precursors, preventing viral replication [1, 2].

81 Nirmatrelvir exhibited antiviral activity against SARS-CoV-2 infection in primary human lung alveolar  
82 epithelial cell line (EC50 value of 61.8 nM and EC90 value of 181 nM) after 3 days of drug exposure  
83 [5]. It was shown to have efficacy against the Alpha (B.1.1.7), Gamma (P.1), Delta (B.1.617.2),  
84 Lambda (C.37), Mu (B.1.621) and Omicron (B.1.1.529) SARS-CoV-2 variants [5].

85

### 86 1.2 Pharmacokinetics:

87 After oral administration of a single dose of nirmatrelvir/ritonavir 300 mg/100 mg, the median time  
88 to peak concentration (t<sub>max</sub>) of nirmatrelvir was 3 hours (range 1 to 6 h), indicating a relatively rapid  
89 absorption. The observed geometric mean (CV%) concentration maximum (C<sub>max</sub>) and the area  
90 under the plasma concentration versus time curve from zero to infinity (AUC<sub>inf</sub>) for nirmatrelvir  
91 were 2.21 mg/L (33 %CV) and 23.01  $\mu$ g\*h/mL (23 %CV), respectively [1, 5]. Studies have shown that  
92 nirmatrelvir was moderately bound to plasma proteins (69%) and has a mean apparent volume of  
93 distribution (V<sub>z</sub>/F) of 104.7 L when administered with ritonavir (300 mg nirmatrelvir/100 mg  
94 ritonavir) [1].

95

96 Based on *in vitro* studies, CYP3A4 is the major contributor (99%) to the oxidative metabolism of  
97 nirmatrelvir. However, nirmatrelvir undergoes minimal metabolism when coadministered with  
98 ritonavir resulting in high and persisting plasma concentrations [1, 5]. When the protease inhibitor  
99 metabolism is inhibited by ritonavir, renal elimination become the major route of nirmatrelvir.[1, 5].

100

101 In healthy volunteers after single or multiple oral doses of nirmatrelvir/ritonavir as oral suspension  
102 the half-life ranged from 6.8 to 9.5 h thereby supporting a twice daily dosing administration regimen  
103 [1, 5].

104

### 105 **1.3 Clinical trials:**

106 The first-in-human clinical trial of nirmatrelvir started on September 9<sup>th</sup>, 2020 and was a phase 1B,  
107 placebo-controlled single and multiple intravenous ascending dose (SAD and MAD) study evaluating  
108 the safety, tolerability, and pharmacokinetics in COVID-19 patients [6]<sup>1</sup>. Its efficacy was studied in a  
109 pre-omicron variant era phase 2-3 double-blind, randomized, controlled trial in adult patients with a  
110 laboratory confirmed diagnosis who were symptomatic, unvaccinated, non-hospitalized and at high  
111 risk for progression to severe COVID-19. A total of 2246 adults were randomised to receive either  
112 300 mg of nirmatrelvir along with 100 mg of ritonavir or placebo orally every 12 hours for 5 days [3].  
113 The treatment arm demonstrated a COVID-19–related hospitalization rate of 0.77% (3/389) at 28-  
114 days compared to the placebo arm at 7.01%. (27/385). This led to an absolute risk reduction of  
115 6.32% (95% confidence interval [CI], –9.04 to –3.59; P<0.001) and a relative risk reduction of 87.8%.  
116 Additionally, the COVID-19–related mortality through day 28 was 0% (0/389) in the treatment group  
117 compared to 1.2% (7/385) in the placebo group [3]. Patients treated with nirmatrelvir and ritonavir  
118 had a decrease in SARS-CoV-2 viral load by a factor of ten relative to the placebo at day-5 [3]. Due to  
119 the satisfactory demonstration of efficacy and safety, Paxlovid® received the Emergency Use  
120 Authorisation (EUA) from the US-FDA in December 2021 and conditional marketing authorization by  
121 the EMA in January 2022 as the first oral antiviral drug for treating COVID-19 in the outpatient  
122 setting [8]. Of note, less than 1% of patients included in the trial were immunocompromised.

123

### 124 **1.4 Warnings and Toxicity:**

125 Use of Paxlovid has been associated with potential complications. Dysgeusia, diarrhea, hypertension,  
126 and myalgia are the main adverse drug reactions reported in the phase III randomized clinical trial [2,  
127 4, 5].

128

129

130 The combination of nirmatrelvir/ritonavir has significant and complex drug-drug interactions,  
131 primarily due to ritonavir. A careful review of the patient’s concomitant medications, including over-  
132 the-counter medications, herbal supplements, and recreational drugs should be performed to  
133 minimize the occurrence of any potential drug-drug interactions (DDI) before prescribing  
134 nirmatrelvir/ritonavir [2, 4, 5]. It is suggested that drug interaction potential be comprehensively  
135 checked. As an example, French recommendations on managing DDI with nirmatrelvir/ritonavir have  
136 been published [9] and the website of the University of Liverpool also provides free access to drug  
137 interaction charts [10]. The nature of the drug-drug interactions will be discussed in subsequent  
138 sections of this publication.

139

140 Paxlovid is contraindicated with drugs that are potent CYP3A inducers where significantly reduced  
141 nirmatrelvir or ritonavir plasma concentrations may lead to potential loss of response to SARS-CoV-2  
142 and possible development of resistance.

143

144 On the other hand, ritonavir is a strong inhibitor of cytochrome CYP3A4 and therefore the use of  
145 Paxlovid is contraindicated with drugs that are highly dependent on CYP3A for clearance and for  
146 which elevated concentrations are associated with serious and/or life-threatening reactions [2, 4, 5].  
147 Moreover, nirmatrelvir/ritonavir could also exhibit potential life-threatening interactions in  
148 individuals on immunosuppressive drug (ISD) therapy; which are mainly metabolized by CYP3A4 [2,  
149 4, 5].

150

151 Concomitant drug therapy of nirmatrelvir/ritonavir with ISD requires specific consideration to avoid  
152 elevated ISD concentrations in the toxic range; in this scenario therapeutic drug monitoring can be  
153 beneficial to adjust ISD dosing. This will be the focus of the second part of this publication.

154

## 155 **2. Drug-drug interaction with ritonavir-boosted nirmatrelvir**

156 Nirmatrelvir does not significantly inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 in  
157 vitro test, and it does not induce any CYPs at clinically relevant concentrations. However,  
158 nirmatrelvir has the potential to irreversibly and time-dependently inhibit CYP3A4 and P-  
159 glycoprotein 1 (permeability glycoprotein, P-gp) also known as multidrug resistance protein 1  
160 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) or cluster of differentiation 243  
161 (CD243)[1]. While drug-drug interaction between nirmatrelvir and ritonavir is beneficial in the use of  
162 Paxlovid®; the potent inhibition of 3A4 by ritonavir can lead to other significant drug interactions.  
163 The significant drug-drug interactions in the combination product are primarily due to ritonavir.

164

165 Ritonavir is a substrate of CYP3A and to a lesser extent CYP2D6 and is transported by P-gp [11, 12].  
166 Ritonavir is an inducer of CYP1A2, CYP2C9, CYP2C19, CYP2B6 and UGT1A1. It is a potent inhibitor of  
167 CYP3A and to a lesser extent of CYP2D6, CYP2C8. Ritonavir displays a paradoxical dose and time-  
168 dependent inhibitory/induction effect on CYP3A and on the multidrug efflux transporter P-gp [11].  
169 Some of the specific interactions are discussed below.

170 Of note, inflammation resulting of COVID-19 can also impact metabolism leading to drug-disease  
171 interaction. However, this phenomenon might be stronger in the later stage of infection (i.e the  
172 cytokine storm) than at the early stage, where nirmatrelvir/ritonavir is indicated.

173

### 174 **2.1 CYP3A**

175 Ritonavir is metabolized by CYP3A4 with a Km value of around 20  $\mu\text{M}$ . However, the KI value for  
176 CYP3A4-mediated drug metabolism is 0.015  $\mu\text{M}$  [13]. Ritonavir's potent inhibitory potential is-based  
177 on the efficient blocking of CYP3A4 and CYP3A5 (kinact/KI) and was reported to be as large as 3200  
178 and 667  $\text{min}^{-1}\cdot\text{mM}^{-1}$ , respectively [14]. Studies have shown that ritonavir is a type II ligand that  
179 perfectly fits into the CYP3A4 active site and irreversibly binds to the heme iron via the thiazole

180 nitrogen. This binding results in decreased redox potential of the CYP protein [15]. This is the basis of  
181 the DDI between ritonavir and immunosuppressant drugs such as tacrolimus, ciclosporin, everolimus  
182 and sirolimus that are metabolized by CYP3A. Enzymatic activity can only be restored through *de*  
183 *novo* protein synthesis; therefore, these mechanism-based inhibitions are prolonged *in vivo* and are  
184 observed even after stopping the inhibitors.

185

186 Ritonavir is well acknowledged as a strong CYP3A inhibitor with an inhibitory effect starting from the  
187 first intake and lasting at least 3 days after the end of ritonavir administration. Therefore, ritonavir  
188 has been combined with other drugs as a pharmacokinetic booster such as the prescription for anti-  
189 human immune deficiency virus (HIV) drug and direct acting antiviral (DAA) drug against hepatitis C  
190 virus (HCV). Studies have demonstrated drug interactions with the DAA combination of ombitasvir,  
191 paritaprevir and ritonavir (Viekirax®) and 11 medications in healthy volunteers [16]. While only  
192 formulated with ritonavir 100 mg once daily, the exposure of ketoconazole, digoxin, pravastatin and  
193 rosuvastatin with Viekirax® were increased by up to 105%, 58%, 76% and 161%, respectively, while  
194 omeprazole exposure decreased by approximately 50%. However, during this DDI phase II study, no  
195 clinically meaningful changes in ombitasvir, paritaprevir and ritonavir exposures were observed in  
196 the presence of the 11 medications.

197

## 198 **2.2 P-glycoprotein**

199 Ritonavir is unidirectionally transported by P-gp [17, 18]. Several clinical studies have shown that  
200 ritonavir pre-treatment in healthy subjects slightly decreased renal and non-renal clearance of  
201 digoxin administered orally or intravenously [19, 20]. However, compared with rifampin, digoxin  
202 renal clearance was only reduced with ritonavir pre-treatment. In addition, simultaneous rifampin  
203 administration increased the C<sub>max</sub>, AUC<sub>0-4</sub> and AUC<sub>0-24</sub>, while diminished digoxin renal clearance,  
204 suggesting cis-inhibition on hepatic influx transporter and renal P-gp. The simultaneous  
205 administration of ritonavir increased Time to peak concentration (t<sub>max</sub>) and AUC<sub>0-24</sub>, and lowered  
206 digoxin renal clearance, implying that ritonavir mainly affects digoxin's tubular secretion via P-gp  
207 [21]. Taken together, ritonavir administration would affect mainly the transport activity of renal P-gp  
208 and may only minimally decrease the intestinal and liver P-gp activity following saturation of CYP3A  
209 enzyme. This implies minimal impact of ritonavir on ISD interaction mediated through P-gp.

210

## 211 **2.3 Additional**

212 Ritonavir is a strong activator of the pregnane X receptor (PXR), which regulates the expression of  
213 various metabolic enzymes including CYP1A2, CYP2B6, CYP2C9, CYP2C19 and uridine diphospho-  
214 glucuronosyltransferases (UGTs) [12]. The activities of CYP2C8, CYP2D6, organic anion transport  
215 protein (OATP), and breast cancer resistance protein (BCRP), are decreased in the presence of  
216 ritonavir [12, 17].

217

## 218 **3. Nirmatrelvir/ritonavir with calcineurin inhibitors**

219 The calcineurin inhibitors (CNIs) tacrolimus and ciclosporin are both narrow therapeutic index drugs  
220 [22]. For organ transplant recipients target concentrations of CNIs have been defined, depending on



221 immunological risk, time after transplantation, co-treatment with other immunosuppressant drugs  
222 and other factors [23]. DDI are frequent, as ciclosporin and tacrolimus are metabolized by CYP3A  
223 enzymes (in gut wall and liver) and they are also substrates of P-gp [24], which is expressed at high  
224 levels in the liver, gastrointestinal tract, and kidney [25].

225

226 A formal DDI study in healthy volunteers showed that in the presence of steady-state concentrations  
227 of ritonavir (100 mg once daily) the dose-normalized ciclosporin concentration at 24 hours (C<sub>24</sub>),  
228 and area under the concentration-time curve from time 0 to infinity (AUC<sub>i</sub>) were 15.8-fold and 5.8-  
229 fold higher, respectively [26]. The effect on tacrolimus pharmacokinetics was even more drastic with  
230 a 17-fold and 57-fold rise in dose-normalized tacrolimus C<sub>24</sub> and AUC<sub>i</sub>, accordingly. The half-lives of  
231 ciclosporin and tacrolimus increased from 7 to 25 h and 32 to 232 h, correspondingly. For both CNIs  
232 the effect on C<sub>max</sub> was smaller, indicating that the reduced clearance by the liver as more likely the  
233 primary mechanism of the interaction than increased oral bioavailability. Thus, these results  
234 suggests that CYP3A inhibition, rather than P-gp, is the primary mechanism of this interaction.  
235 Keeping the same dose of tacrolimus following initiation ritonavir treatment will lead to an  
236 extremely high tacrolimus exposure within 24 hours. There is a need for a significant dose reduction,  
237 to avoid potentially toxic concentrations. For anti-HIV therapies in the context of liver  
238 transplantation, it has been suggested that a dose reduction of tacrolimus as low as 0.5 or 1.0 mg  
239 once a week when co-administered with ritonavir boosted lopinavir therapy is necessary [27].

240

241 Drug interaction with both CNIs is significant and may lead to toxic concentrations of CNIs for a  
242 prolonged period of time; however, monitoring of the magnitude of the interaction through drug  
243 concentration measurements can provide a way to manage this potentially dangerous interaction in  
244 those patients who may simultaneously need both drugs.

245

### 246 **3.1 Recommendations**

#### 247 **3.1.1 Tacrolimus**

248 For most patients, it seems best to discontinue tacrolimus 12h before nirmatrelvir/ritonavir therapy  
249 is started. The pre-dose concentration measured at the time of starting nirmatrelvir/ritonavir is  
250 expected to be maintained at about 75% of the initial concentration at the end of the 5 days of the  
251 antiviral treatment, whereas the magnitude of change in tacrolimus total exposure (AUC<sub>0-120h</sub>) has  
252 been more difficult to estimate. On the other hand, in the context of an active COVID-19, a small  
253 reduction in the exposure of the ISD may contribute to faster viral clearance. If possible, we  
254 recommend a “keep it simple” approach and discontinue tacrolimus during the entire 5-days of  
255 antiviral treatment with nirmatrelvir/ritonavir.

256

257 A less radical alternative and intended only for high-risk patients (patients in the early post-  
258 transplant period or those with a high risk of rejection) would be to administer a small tacrolimus  
259 dose (one eighth of standard dose) on day 1 of nirmatrelvir/ritonavir therapy (with no further dosing  
260 for the next five days at least) to maintain a certain level of tacrolimus exposure during the next  
261 consecutive 5 days of nirmatrelvir/ritonavir therapy. This approach also has the advantage of

262 maintaining an exposure (considering  $AUC_{0-120h}$ ) after antiviral treatment initiation closer to the  
263 exposure provided by the patients' initial dosage before nirmatrelvir/ritonavir initiation. Such a  
264 strategy should be supported by a close collaboration between pharmacologists and clinicians (table  
265 1).

266

267 Upon discontinuation of nirmatrelvir/ritonavir, CYP3A activity will recover with time. The half-life of  
268 ritonavir is short (3-5 hours), but published data suggest that it may take 3 days for the CYP3A  
269 activity to completely restore, achieving after 48h almost 75% of the metabolic activity [28].

270 Therefore, a pragmatic approach would be to extend the temporary discontinuation of tacrolimus  
271 treatment with a few more days with tacrolimus exposure under close surveillance of and cautious  
272 dosing. After 7-8 days tacrolimus can be reintroduced, either in the dose given prior  
273 nirmatrelvir/ritonavir treatment or based on measured tacrolimus concentrations at the time of re-  
274 starting tacrolimus treatment (as suggested by Lange et al. [29]).

275

### 276 **3.1.2 Ciclosporin**

277 For ciclosporin the impact of ritonavir is somewhat smaller than for tacrolimus. Nevertheless,  
278 ciclosporin over-exposure accompanied by signs of severe nephrotoxicity has been reported in  
279 patients on ritonavir [30]. Following nirmatrelvir/ritonavir introduction, the total daily dose of  
280 ciclosporin should be reduced to 20% of the initial dose and administered once daily to maintain  
281 similar blood ciclosporin concentrations. This degree of dose reduction is comparable to what has  
282 been described with direct antiviral agents [26, 31]. Regular ciclosporin concentration monitoring is  
283 advised to guide dosing, especially after discontinuation of nirmatrelvir/ritonavir (table 1).

284 Therapeutic monitoring (TDM) of tacrolimus and ciclosporin is advised to guide safe dosing (see  
285 dedicated section).

286

### 287 **4. Nirmatrelvir/ritonavir with mTOR inhibitors: everolimus, sirolimus**

288 To date there are no reports on the optimal dosing strategy for mTOR inhibitors (mTORi mechanistic  
289 target of rapamycin) like everolimus and sirolimus, when combined with nirmatrelvir/ritonavir or  
290 other ritonavir formulations. In the clinical trials that were performed, patients who used  
291 medications that are highly dependent on CYP3A4 for clearance such as sirolimus and everolimus  
292 were excluded. To provide tentative dose adjustments for solid organ transplant recipients on  
293 mTORi when starting on nirmatrelvir/ritonavir, we therefore need to rely on the information from  
294 drug interactions which have similar properties with respect to CYP3A mediated metabolism and P-  
295 gp mediated transport inhibition. For everolimus and sirolimus there are only a small number of  
296 retrospective reports that could provide guidance to what would be the appropriate dosing strategy.  
297 A study of sirolimus dosing requirement in patients on HIV therapy with ritonavir combination, 1/10  
298 to 1/20 of the typical dose of sirolimus has been recommended [32].

299

300 In a cross-over study of 12 healthy subjects, a single oral everolimus dose of 2 mg was given on day 1  
301 under fasting conditions. Starting on day 10, ketoconazole 200 mg was administered orally every 12  
302 hours and four days later (day 13) everolimus was given again, at a dose of 1 mg. When the results

303 were normalized to a 2 mg dose for comparison, the C<sub>max</sub> increased on average 3.9-fold (90% CI,  
304 3.4-4.6) while AUC increases were clustered largely in the range from 11.2-fold to 17.5-fold (n = 11)  
305 with ketoconazole. The average increase in AUC across all subjects was 15.0-fold (90% CI, 13.6-16.6).  
306 Everolimus half life increased from an average of 30 (SD=4) to 56 (SD=5) h [33]. Although the results  
307 were obtained with the combination of ketoconazole and not with ritonavir, they indicate the  
308 potential influence of CYP3A4 and P-gp inhibition on changing in everolimus exposure. It is expected  
309 that the effect of ritonavir will be much greater.

310

311 A 35-year-old patient with COVID-19 developed a very high everolimus concentration during co-  
312 treatment with lopinavir/ritonavir (400/100 mg BID). The everolimus dose was initially reduced by  
313 1/3 but pre-dose concentrations reached a maximum of 31.1 ng/mL. The authors recommended  
314 immediate withdrawal of mTORi therapy and close monitoring of blood concentrations, clinical  
315 status, and signs of drug toxicity [34].

316

317 A recent study included adult transplant recipients treated with nirmatrelvir/ritonavir for five days,  
318 among these patients, 3 were on everolimus and 1 on sirolimus [35]. According to the protocol [29],  
319 the mTORi was withheld at the start of nirmatrelvir/ritonavir. The most recent mTORi pre-dose  
320 concentration had been measured 77 days (IQR, 58 - 140) before the start of nirmatrelvir/ritonavir  
321 and these concentrations averaged 4.8 ng/mL (IQR, 3 - 4.9). After completion of the  
322 nirmatrelvir/ritonavir, two patients had undetectable concentrations on day 7 and day 9 while the  
323 third patient had 1.4 ng/mL on day 8. The patient on sirolimus had a trough concentration of 5  
324 ng/mL 13 days prior to starting nirmatrelvir/ritonavir and 9.5 ng/mL on day 14. Another case report  
325 advised sirolimus dosage reductions to 1.5 mg per week and 1 mg per 14 days [36].

326

#### 327 **4.1 Recommendations**

328 Based on these very limited observations, the following is recommended for the dosing of mTORi  
329 during and following nirmatrelvir/ritonavir treatment:

- 330 • Approximately 12 hours before nirmatrelvir/ritonavir initiation, the mTORi should be put on  
331 hold. From the day after cessation of nirmatrelvir/ritonavir, the mTORi may be re-introduced  
332 in one fifth of the original dose, and the dose may be increased by twenty percent each day  
333 or according the measured mTORi trough concentrations [37]. The timing and selection of  
334 dose for re-introduction of the mTORi may also depend on which combination of other  
335 immunosuppressants are used and how important the contribution from mTORi in the  
336 immunosuppressive regimen.

337

338 Alternatively, if it is considered important to avoid subtherapeutic mTORi concentrations, and given  
339 the low risk of immediate adverse drug reaction with these drugs, another strategy that can be  
340 considered is as follows:

- 341       • A microdose of 1/8<sup>th</sup> of the patient’s initial daily dose should be given on days 1, 3 and 5  
342       after starting nirmatrelvir/ritonavir, and the initial treatment dosage could be restarted on  
343       day 7 (table 1).  
344

345 It is recommended to frequently monitor immunosuppressant drug levels, at least right before dose  
346 administration and shortly after the end of nirmatrelvir/ritonavir treatment (see dedicated section).  
347

## 348 **5. Nirmatrelvir/ritonavir with mycophenolic acid**

349 Mycophenolic acid (MPA), administered as a prodrug (mycophenolate mofetil, the  
350 morpholinoethylester of MPA) or an enteric-coated salt (mycophenolate sodium), is one of the most  
351 important drugs for the immunosuppressive regimen in organ transplant recipients. During viral  
352 infections, MPA is usually the first immunosuppressive drug, which dosage is decreased if not  
353 discontinued [38]. The drug has also been shown to strongly decrease SARS-CoV-2 vaccine efficacy  
354 [39]. Therefore, therapeutic management of transplant recipients infected with SARS-CoV-2 requires  
355 careful review and a special consideration should be given to potential interactions with approved  
356 COVID-19 treatments like nirmatrelvir/ritonavir.  
357

358 The metabolism of MPA is extensive and mostly occurs in the liver, intestine, and kidney through the  
359 uridine 5'-diphospho-glucuronosyltransferase (UGT) system. The main UGT isoforms involved in  
360 MPA glucuronidation are UGT1A9 and 2B7 [40, 41]. The glucuronidation pathway produces a major  
361 metabolite, MPA 7-O-glucuronide (MPAG), which is inactive. A minor phase 1 metabolite from  
362 human cytochrome P450 isoforms, CYP3A4 and CYP3A5, the 6-O-desmethyl-MPA (DM-MPA) and its  
363 related glucuronide were also identified in blood and urine from transplant patients [42].  
364

365 Expected DDI with nirmatrelvir/ritonavir, may result from ritonavir being an inhibitor and inducer of  
366 UGT. Different studies have underscored the distinct effects of ritonavir on UGT isoforms. Ritonavir  
367 has been shown *in vitro* to consistently inhibit UGT1A1, UGT1A3 and UGT1A4 and weakly inhibit  
368 UGT1A6, UGT1A9 and 2B7 (IC<sub>50</sub>>100µM) [43]. On the other hand, ritonavir has been shown to  
369 induce UGTs, in clinical studies as it significantly decreased systemic exposure to some drugs  
370 eliminated from the body by the glucuronidation pathway like ethinyl oestradiol [44]and lamotrigine  
371 [45].  
372

373 Ritonavir seems to only weakly interact with UGT isoforms (1A9 and 2B7) involved in MPA  
374 metabolism as evidenced by the absence of significant modification in AUC in a hepatitis C virus-  
375 infected patient treated with the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir and  
376 MPA for vasculitis [46]. Moreover, a successful recovery from COVID-19 has been reported in a  
377 patient with systemic lupus erythematosus treated concomitantly with lopinavir/ritonavir and the  
378 SLE drugs including mycophenolic acid [47]. Overall, a limited impact of nirmatrelvir/ritonavir is  
379 expected on MPA metabolism and exposure.  
380

381 **5.1 Recommendations**

382 Given the short duration (5 days) of nirmatrelvir/ritonavir treatment, and because of the low  
383 potential pharmacokinetic interaction, there is no need to adjust MPA dose from an exposure point  
384 of view. However, in solid organ transplant patients with COVID-19 the first drug to be temporarily  
385 discontinued to allow clearance of the virus is MPA (table 1).

386

387 **6. Nirmatrelvir/ritonavir with corticosteroids**

388 Corticosteroids are an integral part of induction and maintenance immunosuppressive regimens in  
389 solid organ transplantation. Corticosteroids are also a drug category that is used in acute therapy but  
390 at the severe, advanced stage of COVID-19 infection. Prednisone, prednisolone and  
391 methylprednisolone are the most commonly used synthetic corticosteroids in transplant recipients.  
392 Prednisone is a prodrug converted through first-pass metabolism by 11- $\beta$ -hydroxydehydrogenase to  
393 its active form, prednisolone [48].

394

395 Both prednisolone and prednisone undergo 6 $\beta$ -hydroxylation via the CYP3A4 metabolic pathway and  
396 are inducers of multidrug associated resistance protein 2 (MRP2), as well as substrates, inhibitors,  
397 and inducers of P-gp [49, 50]. Corticosteroid clearance has been reported to be significantly reduced  
398 in patients on ritonavir-boosted protease inhibitors resulting in increased concentration [51]. In  
399 these patients, the higher exposure has been associated with bone toxicities (e.g., osteonecrosis)  
400 and Cushing syndrome [52]. In the French Pharmacovigilance Database, antiretroviral-boosting  
401 agents in combination with corticosteroids were incriminated in several cases of iatrogenic Cushing  
402 syndrome but this has only been reported in chronic treatment and is unlikely to happen during a 5-  
403 day treatment course with ritonavir [53].

404

405 **6.1 Recommendations**

406 Nirmatrelvir/ritonavir combination with corticosteroids in transplant patients could presumably lead  
407 to a temporary increase in prednisolone exposure due to CYP3A4 and P-glycoprotein inhibition. We  
408 recommend maintaining the same dosage of corticosteroid during the 5-day nirmatrelvir/ritonavir  
409 course (table 1).

410

411 **7. Therapeutic drug monitoring of immunosuppressive drugs with nirmatrelvir/ritonavir**

412 **7.1 TDM recommendations for CNIs to modulate DDIs with COVID-19 PI-based treatment.**

413 The primary objective of TDM is to minimize the toxicity of immunosuppressant drugs while  
414 preventing any under- and over-immunosuppression possibly leading to graft rejection due to  
415 improper discontinuation or of immunosuppression, or toxicity, respectively. Here we provide some  
416 general guidance for monitoring patients simultaneously on nirmatrelvir/ritonavir and ISDs. They are  
417 also summarized in table 1.

418

419 When tacrolimus is discontinued before the antiviral treatment, as proposed in these  
420 recommendations, there is limited risk of toxicity. Given the fact that nirmatrelvir/ritonavir

421 treatment has been designed for outpatient, it is possible to avoid TDM during the 5-day course  
422 unless there's a safe way to apply it (ideally auto-sampling at home).

423

424 The same conclusion can be formulated for ciclosporin. It is important to note that blood  
425 concentration vs time curve of CNIs combined with ritonavir is flat, with a low C<sub>max</sub> (related to the  
426 low dose) and an almost horizontal slope (given the long half-life). As a result, the relationship  
427 between the pre-dose concentration and the AUC is different from the situation where CNI is taken  
428 twice daily in a much higher dose. The mean AUC in ritonavir treated patients was 40 % lower  
429 compared with the AUC's patients not co-treated with ritonavir, when similar trough levels were  
430 targeted [54].

431

432 In case of using small tacrolimus boost (one eighth of standard dose corresponding to a 40-fold dose  
433 reduction with respect to the five previous days of tacrolimus treatment) on day 1 of  
434 nirmatrelvir/ritonavir therapy, for hospitalized patients, patients at high-risk of rejection or at the  
435 initial post-operative period, a more comprehensive TDM approach can be proposed. This may  
436 include early two-sample points (e.g. just before starting nirmatrelvir/ritonavir, at the end of day-1  
437 and day-2) to capture the elimination rate constant of the drug, inform patient's exposure by  
438 approximating the AUC and help defining the time to restart drug dosing. This approach will prevent  
439 toxic tacrolimus exposure and minimize levels falling below the target concentrations. For tacrolimus  
440 and ciclosporin TDM, the trough concentration is more feasible to obtain but the AUC may better  
441 reflect the impact of DDIs in the whole PK profile [23]. These patients may benefit from limited  
442 sampling strategy, with Bayesian estimation of the total AUC, and dried blood spot analysis should  
443 be considered, particularly for tacrolimus [55, 56].

444

445 Given that 70-90% of CYP3A enzyme activity can be expected to recover at day+3 after ritonavir  
446 discontinuation of nirmatrelvir/ritonavir, TDM can also be proposed at the time of CNI treatment  
447 restoration or shortly thereafter. If the treatment with nirmatrelvir/ritonavir would be continued for  
448 a much longer time than just 5 days, it would make sense to aim for higher pre-dose target  
449 concentrations [57].

450

## 451 **7.2 TDM recommendations for mTORi to modulate DDIs with COVID-19 PI-based treatment.**

452 For sirolimus and everolimus similarly to tacrolimus in terms of interactions with boosted PIs are  
453 expected although less-well defined [32]. If mTOR is withdrawn, ideally, mTOR concentrations  
454 should be monitored before starting the antiviral drug. Further dose adjustments will be necessary  
455 to reach target concentrations. In case of using a microdose of 1/8<sup>th</sup> of the patient's initial daily dose  
456 given on day-1, -3 and -5, trough concentration may be measured on day-3 of antiviral treatment to  
457 potentially adjust the subsequent dose. In any case, when mTORi is re-introduced, trough  
458 concentrations should be monitored every second day until stable on a fixed dose and mTORi should  
459 be restarted according to the TDM results. If out of therapeutic range, measurements should be  
460 repeated until concentration is within range and then mTORi dose restarted or adjusted [58]. Again,

461 the implementation of TDM in an outpatient setting can be facilitated using a microsampling  
462 approach.

463

### 464 **7.3 TDM recommendations for mycophenolic acid to modulate DDIs with COVID-19 PI-based** 465 **treatment.**

466 If mycophenolic acid treatment is maintained during the antiviral therapy, TDM can be performed, if  
467 needed, according to locally practice. This would help generating more data on this topic, including  
468 careful descriptions of case reports. Until such data are available, TDM might be a useful tool to  
469 maintain adequate exposure of MPA, for example by using a limited sampling strategy or a Bayesian  
470 approach [58].

471

## 472 **8. Conclusion**

473 Combining nirmatrelvir/ritonavir with narrow therapeutic index drugs metabolized by CYP3A4 and P-  
474 gp is challenging. This is particularly true for tacrolimus and to a lesser extent for ciclosporin,  
475 everolimus and sirolimus. Data from DDI studies between ISD and potent CYP3A4 inhibitors obtained  
476 in the field of HIV and HCV enables the generation of recommendations for dosage adjustments for  
477 these drugs and to secure their prescription during antiviral treatment. While not easy to implement  
478 in an outpatient setting, TDM may be a useful tool to confirm that drug adjustments are appropriate  
479 in a specific case and to help reintroducing ISDs at the end of nirmatrelvir/ritonavir treatment. A  
480 TDM approach during the treatment also appears appropriate when a strict drug exposure  
481 conservation must be ensured.

482

483

484

485

486 **References:**

487

- 488 1. *The U.S. Food and Drug Administration (FDA). Fact Sheet For Healthcare Providers:*  
489 *Emergency Use Authorization For Paxlovid.* <https://www.fda.gov/media/155050/download>.  
490 March 18, 2022 03/21/2022].
- 491 2. *National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus*  
492 *disease 2019 (COVID-19) treatment guidelines.*  
493 [https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section\\_171.pdf](https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section_171.pdf).  
494 February 24, 2022 02/28/2022].
- 495 3. Hammond, J., et al., *Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.* N  
496 Engl J Med, 2022.
- 497 4. Cohen, P. *COVID-19: Outpatient evaluation and management of acute illness in adults.*  
498 *UpToDate.* UpToDate Mar 21, 2022 March 22, 2022]; Available from:  
499 [https://www.uptodate.com/contents/covid-19-outpatient-evaluation-and-management-of-](https://www.uptodate.com/contents/covid-19-outpatient-evaluation-and-management-of-acute-illness-in-adults)  
500 [acute-illness-in-adults](https://www.uptodate.com/contents/covid-19-outpatient-evaluation-and-management-of-acute-illness-in-adults)
- 501 5. *European Medicines Agency (EMA): Paxlovid European public assessment report (EPAR)*  
502 [https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-](https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf)  
503 [information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf). January 28, 2022 03/22/2022].
- 504 6. *ClinicalTrials.gov.* <https://clinicaltrials.gov/ct2/show/record/NCT04535167>. 03/21/2022].
- 505 7. *ClinicalTrials.gov.* <https://clinicaltrials.gov/ct2/show/NCT04756531>. 03/21/2022].
- 506 8. *The U.S. Food and Drug Administration (FDA). Emergency Use Authorization 105 Paxlovid*  
507 *(nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use)*  
508 <https://www.fda.gov/media/155071/download>. December 22, 2021 03/22/2022].
- 509 9. Lemaitre, F., et al., *Management of drug-drug interactions with nirmatrelvir/ritonavir in*  
510 *patients treated for Covid-19: Guidelines from the French Society of Pharmacology and*  
511 *Therapeutics (SFPT).* Therapies, 2022.
- 512 10. *Liverpool Drug Interactions Group. COVID-19 Drug Interactions,* [https://www.covid19-](https://www.covid19-druginteractions.org/)  
513 [druginteractions.org/](https://www.covid19-druginteractions.org/) April 25, 2022];
- 514 11. Foisy, M.M., E.M. Yakiwchuk, and C.A. Hughes, *Induction effects of ritonavir: implications for*  
515 *drug interactions.* Ann Pharmacother, 2008. **42**(7): p. 1048-59.
- 516 12. Cattaneo, D., M.V. Cossu, and G. Rizzardini, *Pharmacokinetic drug evaluation of ritonavir*  
517 *(versus cobicistat) as adjunctive therapy in the treatment of HIV.* Expert Opin Drug Metab  
518 Toxicol, 2019. **15**(11): p. 927-935.
- 519 13. Zhou, S.F., et al., *Clinically important drug interactions potentially involving mechanism-*  
520 *based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.* Ther  
521 Drug Monit, 2007. **29**(6): p. 687-710.
- 522 14. Ernest, C.S., 2nd, S.D. Hall, and D.R. Jones, *Mechanism-based inactivation of CYP3A by HIV*  
523 *protease inhibitors.* J Pharmacol Exp Ther, 2005. **312**(2): p. 583-91.



- 524 15. Sevrioukova, I.F. and T.L. Poulos, *Structure and mechanism of the complex between*  
525 *cytochrome P4503A4 and ritonavir*. Proc Natl Acad Sci U S A, 2010. **107**(43): p. 18422-7.
- 526 16. Badri, P.S., et al., *Drug Interactions with the Direct-Acting Antiviral Combination of*  
527 *Ombitasvir and Paritaprevir-Ritonavir*. Antimicrob Agents Chemother, 2016. **60**(1): p. 105-  
528 14.
- 529 17. Pal, D. and A.K. Mitra, *MDR- and CYP3A4-mediated drug-drug interactions*. J Neuroimmune  
530 Pharmacol, 2006. **1**(3): p. 323-39.
- 531 18. Huisman, M.T., et al., *P-glycoprotein limits oral availability, brain, and fetal penetration of*  
532 *saquinavir even with high doses of ritonavir*. Mol Pharmacol, 2001. **59**(4): p. 806-13.
- 533 19. Penzak, S.R., et al., *Ritonavir decreases the nonrenal clearance of digoxin in healthy*  
534 *volunteers with known MDR1 genotypes*. Ther Drug Monit, 2004. **26**(3): p. 322-30.
- 535 20. Ding, R., et al., *Substantial pharmacokinetic interaction between digoxin and ritonavir in*  
536 *healthy volunteers*. Clin Pharmacol Ther, 2004. **76**(1): p. 73-84.
- 537 21. Kirby, B.J., et al., *Complex drug interactions of the HIV protease inhibitors 3: effect of*  
538 *simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion*.  
539 Drug Metab Dispos, 2012. **40**(3): p. 610-6.
- 540 22. Neuberger, J.M., et al., *Practical Recommendations for Long-term Management of*  
541 *Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical*  
542 *Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT)*  
543 *Group*. Transplantation, 2017. **101**(4S Suppl 2): p. S1-S56.
- 544 23. Brunet, M., et al., *Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second*  
545 *Consensus Report*. Ther Drug Monit, 2019. **41**(3): p. 261-307.
- 546 24. van Gelder, T., *Drug interactions with tacrolimus*. Drug Saf, 2002. **25**(10): p. 707-12.
- 547 25. Thiebaut, F., et al., *Cellular localization of the multidrug-resistance gene product P-*  
548 *glycoprotein in normal human tissues*. Proc Natl Acad Sci U S A, 1987. **84**(21): p. 7735-8.
- 549 26. Badri, P., et al., *Pharmacokinetics and dose recommendations for cyclosporine and*  
550 *tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir*. Am J Transplant,  
551 2015. **15**(5): p. 1313-22.
- 552 27. Jain, A.B., et al., *Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood*  
553 *concentration in liver transplantation patients*. Liver Transpl, 2003. **9**(9): p. 954-60.
- 554 28. Katzenmaier, S., et al., *Determining the time course of CYP3A inhibition by potent reversible*  
555 *and irreversible CYP3A inhibitors using A limited sampling strategy*. Clin Pharmacol Ther,  
556 2011. **90**(5): p. 666-73.
- 557 29. Lange, N.W., et al., *Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug*  
558 *interactions with transplant immunosuppressants*. Am J Transplant, 2022.
- 559 30. Gregoor, P.J., et al., *Cyclosporine and triple-drug treatment with human immunodeficiency*  
560 *virus protease inhibitors*. Transplantation, 1999. **68**(8): p. 1210.

- 561 31. Mori, T., et al., *Drug interaction between voriconazole and calcineurin inhibitors in allogeneic*  
562 *hematopoietic stem cell transplant recipients*. Bone Marrow Transplant, 2009. **44**(6): p. 371-  
563 4.
- 564 32. Krown, S.E., et al., *Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma:*  
565 *an AIDS Malignancy Consortium study*. J Acquir Immune Defic Syndr, 2012. **59**(5): p. 447-54.
- 566 33. Kovarik, J.M., et al., *Blood concentrations of everolimus are markedly increased by*  
567 *ketocoazole*. J Clin Pharmacol, 2005. **45**(5): p. 514-8.
- 568 34. Meziyerh, S., et al., *Severe COVID-19 in a renal transplant recipient: A focus on*  
569 *pharmacokinetics*. Am J Transplant, 2020. **20**(7): p. 1896-1901.
- 570 35. Salerno, D.M., et al., *Early clinical experience with nirmatrelvir/ritonavir for the treatment of*  
571 *COVID-19 in solid organ transplant recipients*. Am J Transplant, 2022.
- 572 36. Dolman, G.E., P. Selby, and W.T. Gelson, *Ombitasvir/paritaprevir/ritonavir plus dasabuvir*  
573 *regimen may be used safely in combination with sirolimus for the treatment of chronic*  
574 *hepatitis C*. BMJ Case Rep, 2018. **2018**.
- 575 37. Zijp, T.R., et al., *Important Interactions of Immunosuppressants With Experimental Therapies*  
576 *for Novel Coronavirus Disease (COVID-19): How to Act*. Ther Drug Monit, 2020. **42**(4): p. 652-  
577 653.
- 578 38. Lai, Q., et al., *SARS-CoV2 and immunosuppression: A double-edged sword*. Transpl Infect Dis,  
579 2020. **22**(6): p. e13404.
- 580 39. Rabinowich, L., et al., *Low immunogenicity to SARS-CoV-2 vaccination among liver transplant*  
581 *recipients*. J Hepatol, 2021. **75**(2): p. 435-438.
- 582 40. Picard, N., et al., *Identification of the UDP-glucuronosyltransferase isoforms involved in*  
583 *mycophenolic acid phase II metabolism*. Drug Metab Dispos, 2005. **33**(1): p. 139-46.
- 584 41. Mackenzie, P.I., *Identification of uridine diphosphate glucuronosyltransferases involved in*  
585 *the metabolism and clearance of mycophenolic acid*. Ther Drug Monit, 2000. **22**(1): p. 10-3.
- 586 42. Picard, N., et al., *Characterization of a phase 1 metabolite of mycophenolic acid produced by*  
587 *CYP3A4/5*. Ther Drug Monit, 2004. **26**(6): p. 600-8.
- 588 43. Zhang, D., et al., *In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other*  
589 *HIV protease inhibitors and the relationship of this property to in vivo bilirubin*  
590 *glucuronidation*. Drug Metab Dispos, 2005. **33**(11): p. 1729-39.
- 591 44. Ouellet, D., et al., *Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy*  
592 *female volunteers*. Br J Clin Pharmacol, 1998. **46**(2): p. 111-6.
- 593 45. van der Lee, M.J., et al., *Lopinavir/ritonavir reduces lamotrigine plasma concentrations in*  
594 *healthy subjects*. Clin Pharmacol Ther, 2006. **80**(2): p. 159-68.
- 595 46. Lemaitre, F., et al., *Managing Drug-Drug Interaction Between Ombitasvir,*  
596 *Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil*. Ther Drug Monit, 2017. **39**(4):  
597 p. 305-307.

- 598 47. He, F., et al., *Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19*  
599 *patient with systemic lupus erythematosus: a case report and review*. Clin Rheumatol, 2020.  
600 **39**(9): p. 2803-2810.
- 601 48. Lindenfeld, J., et al., *Drug therapy in the heart transplant recipient: part II:*  
602 *immunosuppressive drugs*. Circulation, 2004. **110**(25): p. 3858-65.
- 603 49. Christians, U., et al., *Active drug transport of immunosuppressants: new insights for*  
604 *pharmacokinetics and pharmacodynamics*. Ther Drug Monit, 2006. **28**(1): p. 39-44.
- 605 50. Bergmann, T.K., et al., *Clinical pharmacokinetics and pharmacodynamics of prednisolone and*  
606 *prednisone in solid organ transplantation*. Clin Pharmacokinet, 2012. **51**(11): p. 711-41.
- 607 51. Lauterio, A., et al., *Successful recovery from severe COVID-19 pneumonia after kidney*  
608 *transplantation: The interplay between immunosuppression and novel therapy including*  
609 *tocilizumab*. Transpl Infect Dis, 2020. **22**(5): p. e13334.
- 610 52. Penzak, S.R., et al., *Prednisolone pharmacokinetics in the presence and absence of ritonavir*  
611 *after oral prednisone administration to healthy volunteers*. J Acquir Immune Defic Syndr,  
612 2005. **40**(5): p. 573-80.
- 613 53. Peyro-Saint-Paul, L., et al., *Cushing's syndrome due to interaction between ritonavir or*  
614 *cobicistat and corticosteroids: a case-control study in the French Pharmacovigilance*  
615 *Database*. J Antimicrob Chemother, 2019. **74**(11): p. 3291-3294.
- 616 54. van Maarseveen, E.M., et al., *Pretransplantation pharmacokinetic curves of tacrolimus in*  
617 *HIV-infected patients on ritonavir-containing cART: a pilot study*. Transplantation, 2013.  
618 **95**(2): p. 397-402.
- 619 55. Benkali, K., et al., *Population pharmacokinetics and Bayesian estimation of tacrolimus*  
620 *exposure in renal transplant recipients on a new once-daily formulation*. Clin Pharmacokinet,  
621 2010. **49**(10): p. 683-92.
- 622 56. Velghe, S., R. De Troyer, and C. Stove, *Dried blood spots in therapeutic drug monitoring and*  
623 *toxicology*. Expert Opin Drug Metab Toxicol, 2018. **14**(1): p. 1-3.
- 624 57. van Maarseveen, E.M., A.D. van Zuilen, and T. Mudrikova, *Outcomes of kidney*  
625 *transplantation in HIV-infected recipients*. N Engl J Med, 2011. **364**(7): p. 683; author reply  
626 684.
- 627 58. Bergan, S., et al., *Personalized Therapy for Mycophenolate: Consensus Report by the*  
628 *International Association of Therapeutic Drug Monitoring and Clinical Toxicology*. Ther Drug  
629 Monit, 2021. **43**(2): p. 150-200.
- 630

**Table 1. Recommendations for immunosuppressive drugs adjustment when combined with nirmatrelvir/ritonavir, for restart strategies of the immunosuppressive drugs and proposed therapeutic drug monitoring.**

AUC: area under the curve of drug concentrations; TDM: therapeutic drug monitoring.

| Immunosuppressive agent  | Recommended immunosuppressive drug adjustment                              | Alternative immunosuppressive drug adjustment                                      | Restart of the immunosuppressive drug     | Proposition for TDM (if feasible)  |
|--------------------------|--|--|---|--|
| <b>Tacrolimus</b>        | Discontinue tacrolimus 12h before nirmatrelvir/ritonavir initiation        | Administer 1/8 <sup>th</sup> of the usual daily dose on day-1 and then discontinue | Tacrolimus can be reintroduced on day-7/8 | Two sample time points to capture drug elimination and TDM at treatment restoration or shortly thereafter (if possible an AUC monitoring should be conducted)  |
| <b>Cyclosporine</b>      | Reduced to 20% of the initial dose from day-1                              | -  | Progressively reintroduced from day-6     | Trough concentrations (be aware that pharmacokinetic profile can change during the antiviral treatment) and TDM at treatment restoration or shortly thereafter |
| <b>m-TOR inhibitors</b>  | Discontinue m-TOR inhibitor 12h before nirmatrelvir/ritonavir initiation   | Administer 1/8 <sup>th</sup> of the usual daily dose on day-1, -3 and -5           | m-TOR can be reintroduced on day-7        | Trough concentrations (on day-3 in case of applying the alternative drug adjustment) and then TDM at treatment restoration or shortly thereafter               |
| <b>Mycophenolic acid</b> | No need to adjust drug dosage given the short antiviral treatment duration | Mycophenolic acid can be discontinued in some cases                                | -   | TDM according to local practice  |
| <b>Corticosteroids</b>   | No need to adjust drug dosage  | -  | -   | No need for TDM  |